Related references
Note: Only part of the references are listed.Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
Simona Guerzoni et al.
NEUROLOGICAL SCIENCES (2022)
Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study
Pablo Irimia et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Erenumab Discontinuation After 12-Month Treatment A Multicentric, Observational Real-Life Study
Francesca Schiano di Cola et al.
NEUROLOGY-CLINICAL PRACTICE (2021)
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
Messoud Ashina et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study
Piero Barbanti et al.
HEADACHE (2021)
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
Fabrizio Vernieri et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies
Richard B. Lipton et al.
CEPHALALGIA (2021)
Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency
Ryotaro Ishii et al.
HEADACHE (2021)
Proposed new diagnostic criteria for chronic migraine
Mona Ameri Chalmer et al.
CEPHALALGIA (2020)
International Classification of Headache Disorders-ICHD-4 alpha
Peter J. Goadsby et al.
CEPHALALGIA (2020)
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
Dawn C. Buse et al.
HEADACHE (2020)
Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study
Francesca Schiano di Cola et al.
NEUROLOGICAL SCIENCES (2020)
Migraine Progression: A Systematic Review
Dawn C. Buse et al.
HEADACHE (2019)
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability
Richard B. Lipton et al.
HEADACHE (2016)